Rare Diseases Clinical Trial
Official title:
Preferences and Representations Concerning High-throughput Sequencing Technologies in Medical Genetics. The Case of Development Anomalies.
After the use of DNA chips for diagnostic purposes, high-throughput sequencing (HTS) is
transforming the field of developmental diseases, from fundamental research to care.
Nonetheless, before HTS can be transferred to everyday clinical practice, in particular for
expert diagnosis using exome HTS, it is necessary to anticipate the nature of the
information to be given to patients and to parents in order to obtain consent for exome HTS.
The objective in terms of public health is to allow patients with rare diseases to benefit
from innovative technologies in optimal conditions of information and accompaniment.
the objectives of this project are to
1. evaluate the preferences of families of patients with development disorders as regard
to suspicious and incidental findings from HTS before its introduction for diagnostic
purpose,
2. and then, following the exome analyses carried out for diagnostic purposes, describe,
analyse and understand the experience, expectations and reactions of families and
geneticists concerning the diagnostic trajectory in general and at the time the results
of the HTS were announced in particular A methodology that associated quantitative and
qualitative approaches was chosen so as to combine the advantages and overcome the
shortcomings of each: a quantitative study to investigate a large number of patients,
which would ensure a certain representativeness of the population and allow sub-groups
analyses to study the upstream phase concerning indications for high-throughput
sequencing; and a qualitative study, which though it allows only a small number of
patients to be investigated, makes it possible to describe, analyze and understand in
depth the complex downstream phenomena of high-throughput sequencing results
n/a
Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05794217 -
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
|
||
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Completed |
NCT03290469 -
NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants
|
N/A | |
Not yet recruiting |
NCT05955794 -
Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes
|
N/A | |
Recruiting |
NCT04429750 -
Intact Cord Resuscitation in CDH
|
N/A | |
Not yet recruiting |
NCT04152876 -
Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
|
||
Recruiting |
NCT03683966 -
MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
|
||
Not yet recruiting |
NCT04319796 -
European Registry on Rare Neurological Diseases
|
||
Completed |
NCT02736565 -
Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
|
Phase 1 | |
Completed |
NCT05070988 -
Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
|
||
Completed |
NCT03563677 -
Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases
|
N/A | |
Recruiting |
NCT05499091 -
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
|
N/A | |
Completed |
NCT03954652 -
Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"
|
N/A | |
Recruiting |
NCT05703893 -
Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
|
||
Enrolling by invitation |
NCT04703179 -
Rare and Undiagnosed Disease Research Biorepository
|
||
Recruiting |
NCT04024774 -
Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
|
||
Recruiting |
NCT06343558 -
Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
|
||
Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
Enrolling by invitation |
NCT04654000 -
Rheopheresis as Adjuvant Treatment of Calciphylaxis
|
N/A | |
Recruiting |
NCT04651439 -
Severe Bullous Drug Eruption and Filgrastim
|
Phase 2/Phase 3 |